
|Articles|May 1, 2004
Intravitreal triamcinolone may be helpful PDT adjunct for AMD
Fort Lauderdale, FL-Intravitreal triamcinolone may enhance the efficacy of photodynamic therapy (PDT) with verteporfin (Visudyne, QLT Phototherapeutics/Novartis Ophthalmics) and decrease the number of re-treatments for eyes with choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), according to the preliminary results of an open-label study presented by Daniel B. Roth, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
4
PainReform launches development plan for OcuRing-K, readies phase 2 trial
5















































.png)


